EN DE
Watch Tela Bio Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tela Bio Inc (TELA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Tela Bio Inc stock $0.79, price $0.80, that is 1.6% below the price, quality 32 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TB Tela Bio Inc logo Thin data Nov 10, 2026

Tela Bio Inc

TELA · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Fair value $0.7870 · Fairly valued
Expensive Growth (revenue 5y +34.5 %/yr in USD)
Negative equity (buybacks among others)
Insiders bought $186,250 (6M)
Quality 32/100
Loss-making · -51.5% net margin (TTM)
Negative free cash flow
Trails peers (2/7)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Tela Bio Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$14.16 $0.5600 Fair Value $0.7870 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.5600 – $14.16 · fair‑value band $0.5903 – $0.9838 · the $0.8000 price screens above the $0.7870 fair value. As of Nov 10, 2026.

Follow Tela Bio in your weekly email

Every Wednesday you see whether Tela Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy.

Show moreShow less

The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs.

It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Stock analysis

Tela Bio Inc (TELA) currently trades at $0.8000, while our estimate is $0.7870, so the stock looks roughly fairly valued today (gap 1.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5903 (bear) to $0.9838 (bull), the price of $0.8000 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tela Bio Inc reported revenue of $80.3M in FY2025 versus $29.5M in FY2021, a compound +28.5%/yr. Reported net income was −$38.8M in FY2025.

Key figures

Market cap $45.9M Micro · P/S ratio 0.46 · EPS (TTM) $−0.7700 · Net margin −51.5% · Return on equity −617% · Return on assets (EBIT) −48.3% (5-year average) · Operating margin −48.1% · Revenue (TTM) $79.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 43% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −2%, TELA screens richer than that median.

Fair Value

Bear $0.5903 Fair Value $0.7870 Bull $0.9838
Price $0.8000 · Downside -1.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 35
How much profit the company makes from its sales and capital
Quality Growth 66
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 25
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 17
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $186,250, most recently on Sep 17, 2026. Buying cluster

  • BuyJoseph H CapperDirector2× since Sep 14, 2026: 150,000 shares, avg. $1.12$167,500Sep 17, 2026
  • BuyHeather C GetzChief Executive Officer, Director2× since Aug 14, 2026: 27,500 shares, avg. $0.6818$18,750Aug 17, 2026
  • BuyEW Healthcare Partners Fund 2-UGP, LLC10% owner3,604,000 shares at $1.11$4.0MNov 17, 2025

Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+34.5%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−138.8% (2020) → −42.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch TELA, get fair value alerts →

Compare Tela Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −1.6% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −47.7% · Bottom 25%
Net margin (12 months) −51.5% · Bottom 25%
Operating margin (12 months) −48.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −4.5% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 0.58× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)31 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs TELA
DexCom, Inc DXCM $79.92 $89.18 +12% vs TELA
Stryker Corporation SYK $324.29 $358.30 +10% vs TELA
STERIS plc STE $257.12 $279.53 +9% vs TELA
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs TELA
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs TELA
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs TELA
Abbott Laboratories, ABT $110.46 $75.28 −32% vs TELA
Medtronic plc MDT $101.59 $65.61 −35% vs TELA
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs TELA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tela Bio Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tela Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/TELA

Frequently asked questions

Is Tela Bio Inc (TELA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.7870 versus a price of $0.8000, about 2% lower (fairly valued).
What is the fair value of TELA?
Our estimate for Tela Bio Inc is $0.7870 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.8000.
What is the quality score of TELA?
Tela Bio Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tela Bio Inc (TELA)?
Our calculated price target is the estimate of $0.7870 (as of Nov 10, 2026). Cautious scenario $0.5903, optimistic scenario $0.9838. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tela Bio Inc stock forecast for 2026?
Our estimate puts fair value at $0.7870, about 2% lower versus a price of $0.8000 (fairly valued). Cautious scenario $0.5903, optimistic scenario $0.9838. The calculation is refreshed regularly with new filings.
What is the revenue of Tela Bio Inc (TELA)?
Tela Bio Inc reported trailing-twelve-month revenue of about $79.9M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Tela Bio Inc (TELA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tela Bio Inc it is $0.7870 per share (as of Nov 10, 2026), against a price of $0.8000.
Is Tela Bio Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, TELA trades above its calculated fair value: price $0.8000, fair value $0.7870, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TELA?
No. The price is what the market pays today ($0.8000); the fair value is what the company's own numbers justify ($0.7870). For Tela Bio Inc the two are $0.0130 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tela Bio Inc worth?
The market values Tela Bio Inc at about $45.9M (market capitalisation, as of Nov 10, 2026). Per share that is $0.8000; our models calculate a fair value of $0.7870 per share.
What do the bullish and bearish scenarios say about TELA?
Our models span a range for Tela Bio Inc: cautious scenario $0.5903, base $0.7870, optimistic $0.9838 per share (as of Nov 10, 2026, price $0.8000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tela Bio Inc (TELA)?
Balance-sheet figures for Tela Bio Inc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is TELA from its 52-week high?
Tela Bio Inc trades at $0.8000, about 43% below its 52-week high of $1.41 and 43% above the low of $0.5600 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7870 is for.
Which stocks are comparable to Tela Bio Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tela Bio Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.8000, calculated fair value $0.7870 (−2%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Tela Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tela Bio Inc (TELA)?
The closing price on Nov 10, 2026 was $0.8000. Our estimate is $0.7870, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tela Bio Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tela Bio Inc

How large is the market capitalisation of Tela Bio Inc (TELA)?
The market capitalisation of Tela Bio Inc is $45.9M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tela Bio Inc (TELA)?
The price-to-sales ratio of Tela Bio Inc is 0.46 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tela Bio Inc (TELA)?
Earnings per share at Tela Bio Inc are $−0.7700. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tela Bio Inc (TELA)?
The net margin of Tela Bio Inc is −51.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tela Bio Inc (TELA)?
The return on equity (ROE) of Tela Bio Inc is −617% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tela Bio Inc (TELA)?
On an EBIT basis the return on assets of Tela Bio Inc is −48.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tela Bio Inc (TELA)?
The operating margin of Tela Bio Inc is −48.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tela Bio Inc (TELA)?
Revenue at Tela Bio Inc is growing −4.5% versus a year earlier (3y avg +24.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Tela Bio Inc (TELA) generate?
The free cash flow of Tela Bio Inc is −$28.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tela Bio Inc (TELA) carry?
The net debt of Tela Bio Inc is $4.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tela Bio Inc in the live analysis

One click puts Tela Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.